title: Patient-reported outcomes of bimatoprost for eyelash growth: results from a randomized, double-masked, vehicle-controlled, parallel-group study.
abstract: BACKGROUND
  Hypotrichosis of the eyelashes may negatively influence an individual's self-perception and appearance. Assessing the impact of treatment from a patient's perspective may be particularly relevant in trials of aesthetic agents. Once-daily dermal (topically applied) administration of bimatoprost ophthalmic solution 0.03% has been associated with increased eyelash prominence (ie, length, thickness, darkness).
  
  
  OBJECTIVE
  The authors assess patient-reported outcomes (PRO) after treatment with bimatoprost for hypotrichosis of the eyelashes.
  
  
  METHODS
  In this multicenter, double-masked, randomized, vehicle-controlled, parallel clinical trial, 4 PRO questionnaires were distributed to 278 patients (bimatoprost [n = 137] and vehicle [n = 141]). The primary PRO questionnaire was the 23-item Eyelash Satisfaction Questionnaire (ESQ), which measured satisfaction in 3 domains: length, fullness, and overall satisfaction (LFOS); confidence, attractiveness, and professionalism (CAP); and impact on daily routine (DR).
  
  
  RESULTS
  By week 16, the bimatoprost group reported significantly greater improvements from baseline on all ESQ items (P ≤ .0433). These improvements were sustained through the 4-week posttreatment study visit. Patient satisfaction was significantly greater in the bimatoprost group than in the vehicle group for all 3 domains: LFOS (weeks 8-20; P ≤ .0052), CAP (weeks 12-20; P < .0001), and DR (weeks 16 and 20; P ≤ .01).
  
  
  CONCLUSIONS
  The bimatoprost group reported significantly greater levels of positive patient outcomes and satisfaction than the vehicle group across all 23 questions and all 3 domains of the primary PRO questionnaire. These results support the effectiveness, as measured by objective measures and PRO, of once-daily bimatoprost ophthalmic solution 0.03% at producing more prominent eyelashes in adults.
authors.affiliation: sfeyeplastix1@aol.com
authors.forename: Steven
authors.initials: S
authors.lastname: Fagien
authors.forename: John G
authors.initials: JG
authors.lastname: Walt
authors.forename: Jean
authors.initials: J
authors.lastname: Carruthers
authors.forename: Sue Ellen
authors.initials: SE
authors.lastname: Cox
authors.forename: David
authors.initials: D
authors.lastname: Wirta
authors.forename: Emily
authors.initials: E
authors.lastname: Weng
authors.forename: Frederick C
authors.initials: FC
authors.lastname: Beddingfield
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000577:Amides / Q000008:administration & dosage / Q000627:therapeutic use*; D000069580:Bimatoprost; D001828:Body Image; D002170:Canada; D003008:Cloprostenol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017281:Cost of Illness; D004311:Double-Blind Method; D005140:Eyelashes / Q000187:drug effects* / Q000254:growth & development; D005260:Female; D006801:Humans; D007039:Hypotrichosis / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D017060:Patient Satisfaction; D012649:Self Concept; D011795:Surveys and Questionnaires; D013997:Time Factors; D016896:Treatment Outcome; D014481:United States; D055815:Young Adult
chemical_list: D000577:Amides; D009883:Ophthalmic Solutions; D003008:Cloprostenol; D000069580:Bimatoprost
keywords: bimatoprost; cosmetic medicine; eyelash; oculoplastic surgery; patient satisfaction; questionnaire